Search Results

Download scoring documents for this measure. BACK PROMIS Item Bank v1.0 Dyspnea Severity Downloads http://www.healthmeasures.net/score-and-interpret/calculate-scores/scoring-instructions

Download scoring documents for this measure. BACK FLSI-12 Scoring Downloads Download DOC

FHSI Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index - 8 Item Version For patients with Hepatobiliary cancer (liver, bile duct and pancreas); A FACT-Hepatobiliary Symptom Index (a subset of FACT-Hep containing 8 items) LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FHSI measure: MEASURE NAME: Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index - 8 Item Version (FHSI) VERSION: 4 NUMBER OF ITEMS: 8 PATIENT POPULATION: Hepatobiliary cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Hepatobiliary cancer symptom index TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACT-Hep , NFHSI-18 , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FHSI can be obtained by registering for permission. Users are not permitted to translate the FHSI without permission from FACIT.org. Permission from FACIT.org to translate the FHSI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Eid, S., Stromberg, A., Ames, S., Ellis, S., McMasters, K., & Martin, R. Assessment of symptom experience in patients undergoing hepatic resection or ablation. Cancer 2006; 107(11): 2715-2722. doi: 10.1002/cncr.22297. Poplin, E., Feng, Y., Berlin, J., Rothenberg, M., Hochster, H., Mitchell, E., Alberts, S., O’Dwyer, P., Haller, D., Catalano, P., Cella, D., & Benson, A. Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncolology 2009; 27:3778-3785. doi: 10.1200/JCO.2008.20.900. Yount, S., Cella, D., Webster, K., Heffernan, N., Chang, C.-H., Odom, L., & van Gool, R. Assessment of patient-reported clinical outcome in Pancreatic and other Hepatobiliary Cancers: The FACT Hepatobiliary Symptom Index. Journal of Pain & Symptom Management 2002; 24(1): 32-44. doi: 10.1016/s0885-3924(02)00422-0. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Hep Functional Assessment of Cancer Therapy – Hepatobiliary LEARN MORE NFHSI-18 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Hepatobiliary Cancer Symptom Index - 18 Item Version LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

Download this measure in English. BACK FPSI English Downloads Download PDF Download DOC

FACT-AntiA Functional Assessment of Cancer Therapy – AntiAngiogenesis For patients receiving Anti-Angiogenesis therapy LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-AntiA measure: MEASURE NAME: Functional Assessment of Cancer Therapy – AntiAngiogenesis (FACT-AntiA) VERSION: 4 NUMBER OF ITEMS: 50 PATIENT POPULATION: Patient population: Cancer patients 18 years and older receiving anti-angiogenesis treatment RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, AntiAngiogenesis Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT/GOG-NTX , FACT-BRM , FACT-BMT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-AntiA can be obtained by registering for permission. Users are not permitted to translate the FACT-AntiA without permission from FACIT.org. Permission from FACIT.org to translate the FACT-AntiA may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Kaiser K., Beaumont J.L., Webster K., Yount S.E., Wagner L.I., Kuzel T.M., Cella D. Development and validation of the Functional Assessment of Cancer Therapy – Antiangiogenesis subscale. Cancer Med 2015; May 4(5): 690-698. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT/GOG-NTX Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity LEARN MORE FACT-BRM Functional Assessment of Cancer Therapy - Biologic Response Modifiers LEARN MORE FACT-BMT Functional Assessment of Cancer Therapy - Bone Marrow Transplantation LEARN MORE

Download scoring documents for this measure. BACK DMD Scoring Downloads Download PDF

FACIT-AD Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort For patients with Abdominal symptoms LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACIT-AD measure: MEASURE NAME: Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort (FACIT-AD) VERSION: 4 NUMBER OF ITEMS: 30 PATIENT POPULATION: Cancer patients 18 years and older with abdominal discomfort RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Abdominal Discomfort Subscale TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI possible. RELATED MEASURES: FACIT-D , FACT-Ga , FACIT-AI DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACIT-AD can be obtained by registering for permission. Users are not permitted to translate the FACIT-AD without permission from FACIT.org. Permission from FACIT.org to translate the FACIT-AD may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Wenzel, L., Huang, H., Armstrong, D., Walker, J., & Cella, D. Health-Related Quality of Life During and After Intraperitoneal Versus Intravenous Chemotherapy for Optimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 2007; 25(4): 437-443. doi: 10.1200 /JCO.2006.07.3494. Wenzel, L., Huang, H., Cella, D., Walker, J., & Armstrong, D. Validation of FACT/COG-AD subscale for ovarian cancer related abdominal discomfort: A Gynecologic Group Study. Gynecologic Oncology 2008. 110 (1): 60-64. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., & Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., & Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-D Functional Assessment of Chronic Illness Therapy – Diarrhea LEARN MORE FACT-Ga Functional Assessment of Cancer Therapy – Gastric LEARN MORE FACIT-AI Functional Assessment of Chronic Illness Therapy - Ascites Index LEARN MORE

Download scoring documents for this measure. BACK FACT-LUI Scoring Downloads Download PDF Download Excel

Download scoring documents for this measure. BACK PROMIS SF v1.0-Dyspnea-Severity Item Bank http://www.healthmeasures.net/score-and-interpret/calculate-scores/scoring-instructions

PROMIS Pool v1.0 - Dyspnea Activity Motivation Patient Reported Outcomes Measurement Information System Pool - Dyspnea Activity Motivation For patients with dyspnea LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details on the PROMIS Pool v1.0 Dyspnea Activity Motivation MEASURE NAME: PROMIS Pool v1.0 - Dyspnea Activity Motivation VERSION: 1 NUMBER OF ITEMS: 7 PATIENT POPULATION: Dyspnea patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic For permission to implement and administer the measure electronically, please visit: https://www.healthmeasures.net/implement-healthmeasures/administration-platforms ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Activity Motivation TIME FOR COMPLETION: Less than 5 minutes SCORING: PROMIS Scoring Service: http://www.healthmeasures.net/score-and-interpret/calculate-scores/scoring-instructions RELATED MEASURES: FACIT-Dyspnea , PROMIS Pool v1.0 - Dyspnea Activity Requirements , PROMIS Pool v1.0 - Dyspnea Airborne Exposure DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the PROMIS Pool v1.0 - Dyspnea Activity Motivation can be obtained by registering for permission. Users are not permitted to translate the PROMIS Pool v1.0 - Dyspnea Activity Motivation without permission from FACIT.org. Permission from FACIT.org to translate the PROMIS Pool v1.0 - Dyspnea Activity Motivation may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Choi, S., Victorson, D., Yount, S., Anton, S., & Cella, D. Development of a conceptual framework and calibrated item banks to measure patient reported dyspnea severity and related functional limitations. Value in Health 2011; 14: 291-306. Ruo, B., Choi, S., Baker, D., Grady, K., & Cella,D. Development and validation of a computer adaptive test measuring dyspnea in heart failure. Journal of Cardiac Failure 2010; 16(8): 659-668. doi: 10.1016/j.cardfail.2010.03.002. Victorson, D., Anton, S., Hamilton, A., Yount, S., & Cella, D. A conceptual model of the experience of dyspnea and functional limitations in COPD. Value in Health 2009; 12(6): 1018-1025. Yount, S., Choi, S., Victorson, D., Ruo, B., Ray, D., Cella, D., Anton, S., & Hamilton, A. (2011) Brief, valid measures of dyspnea and related functional limitations in chronic obstructive pulmonary disease (COPD). Value in Health 2011; 14: 307-315. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-Dyspnea Functional Assessment of Chronic Illness Therapy - Dyspnea-10 item LEARN MORE PROMIS Pool v1.0 - Dyspnea Activity Requirements Patient-Reported Outcomes Measurement Information System Pool - Dyspnea Activity Requirements LEARN MORE PROMIS Pool v1.0 - Dyspnea Airborne Exposure Patient-Reported Outcomes Measurement Information System Pool - Dyspnea Airborne Exposure LEARN MORE

Download this measure in English. BACK FACIT-Sp English Downloads Download PDF Download DOC

NFLSI-17 Functional Assessment of Cancer Therapy Lung Cancer Symptom Index – 17 Item Version For patients with Lung cancer; a FACT/NCCN-Lung Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The NCCN/FACT Lung Cancer Symptom Index-17 (NFLSI-17) is a brief symptom index for patients with advanced lung cancer. It was developed with input from 50 patients with advanced lung cancer who were recruited from National Comprehensive Cancer Network (NCCN) member institutions and community support agencies, along with 10 physician experts who were recruited from NCCN institutions. Patients reported symptoms associated with their disease in an open-ended format and then completed a checklist of symptoms, rating their 5 most important symptoms. Patient and provider ratings of symptom importance were tabulated to construct NFLSI-17. Patients also completed the Functional Assessment of Cancer Therapy-Lung (FACT-L), which was used to preliminarily validate the NFLSI-17. Based on this input, the NFLSI-17 is composed of 17 priority symptoms, 11 that are disease related, 3 that are treatment related, and 3 that are related to general functional well-being. Data on 15 of 17 NFLSI-17 symptoms showed good internal consistency (alpha = 0.74) and strong association with the FACT-L total and most subscale scores (r = 0.42-0.92). MEASURE NAME: Functional Assessment of Cancer Therapy Lung Cancer Symptom Index – 17 Item Version (NFLSI-17) VERSION: 2 NUMBER OF ITEMS: 17 PATIENT POPULATION: Lung cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side-Effects, Function/Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores available. RELATED MEASURES: FACT-L , FLSI , FLSI-12 , FACT-LCS , FACT-PSI DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NFLSI-17 can be obtained by registering for permission. Users are not permitted to translate the NFLSI-17 without permission from FACIT.org. Permission from FACIT.org to translate the NFLSI-17 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., & Cella, D. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.). The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research. Emerald Group Publishing Inc. 2007; 16: 53-66. doi: 10.1016/S0194-3960(08)16003-6. Yount, S., Beaumont, J., Rosenbloom, S., Cella, D., Patel, J., Hensing, T., Jacobsen, P., Syrjala, K., & Abernethy, A. A brief symptom index for advanced lung cancer. Clinical Lung Cancer 2012; 13(1): 14-23. doi: 10.1016/j.cllc.2011.03.033. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-L Functional Assessment of Cancer Therapy – Lung LEARN MORE FLSI Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 6 Item Version LEARN MORE FLSI-12 Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 12 Item Version LEARN MORE